Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Volker Knappertz

Showing results (21-30 of 43) with videos related to

Pageof 5
Sort By:
Multiple Sclerosis and Related Disorders|July 22, 2015
GLACIER: An open-label, randomized, multicenter study to assess the safety and tolerability of glatiramer acetate 40 mg three-times weekly versus 20 mg daily in patients with relapsing-remitting multiple sclerosisJerry S Wolinsky, T Erik Borresen, Dennis W Dietrich, et al.
Plos One|August 22, 2014
Causes of death among commercially insured multiple sclerosis patients in the United StatesDouglas S Goodin, Michael Corwin, David Kaufman, et al.
Progress in Neurobiology|March 9, 2016
Pharmacogenomics strategies to optimize treatments for multiple sclerosis: Insights from clinical researchIris Grossman, Volker Knappertz, Daphna Laifenfeld, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|July 7, 2017
Comparative utility of disability progression measures in PPMS: Analysis of the PROMiSe data setMarcus W Koch, Gary R Cutter, Gavin Giovannoni, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|December 24, 2011
Relationship between early clinical characteristics and long term disability outcomes: 16 year cohort study (follow-up) of the pivotal interferon β-1b trial in multiple sclerosisDouglas S Goodin, Anthony Traboulsee, Volker Knappertz, et al.
International Journal of MS Care|March 1, 2017
Laquinimod Safety Profile: Pooled Analyses from the ALLEGRO and BRAVO TrialsPer Soelberg Sørensen, Giancarlo Comi, Timothy L Vollmer, et al.
Epilepsia|April 2, 2021
Time to onset of cannabidiol (CBD) treatment effect in Lennox-Gastaut syndrome: Analysis from two randomized controlled trialsMichael Privitera, Hari Bhathal, Matthew Wong, et al.
JAMA Neurology|March 3, 2020
Dose-Ranging Effect of Adjunctive Oral Cannabidiol vs Placebo on Convulsive Seizure Frequency in Dravet Syndrome: A Randomized Clinical TrialIan Miller, Ingrid E Scheffer, Boudewijn Gunning, et al.
JAMA Neurology|December 21, 2020
Add-on Cannabidiol Treatment for Drug-Resistant Seizures in Tuberous Sclerosis Complex: A Placebo-Controlled Randomized Clinical TrialElizabeth A Thiele, E Martina Bebin, Hari Bhathal, et al.
Acta Neuropathologica|July 5, 2014
CD19 as a molecular target in CNS autoimmunityOlaf Stüve, Clemens Warnke, Krystin Deason, et al.
Pageof 5

Showing results (21-30 of 43) with videos related to

Sort By:
Pageof 5
Multiple Sclerosis and Related Disorders|July 22, 2015
GLACIER: An open-label, randomized, multicenter study to assess the safety and tolerability of glatiramer acetate 40 mg three-times weekly versus 20 mg daily in patients with relapsing-remitting multiple sclerosisJerry S Wolinsky, T Erik Borresen, Dennis W Dietrich, et al.
Plos One|August 22, 2014
Causes of death among commercially insured multiple sclerosis patients in the United StatesDouglas S Goodin, Michael Corwin, David Kaufman, et al.
Progress in Neurobiology|March 9, 2016
Pharmacogenomics strategies to optimize treatments for multiple sclerosis: Insights from clinical researchIris Grossman, Volker Knappertz, Daphna Laifenfeld, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|July 7, 2017
Comparative utility of disability progression measures in PPMS: Analysis of the PROMiSe data setMarcus W Koch, Gary R Cutter, Gavin Giovannoni, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|December 24, 2011
Relationship between early clinical characteristics and long term disability outcomes: 16 year cohort study (follow-up) of the pivotal interferon β-1b trial in multiple sclerosisDouglas S Goodin, Anthony Traboulsee, Volker Knappertz, et al.
International Journal of MS Care|March 1, 2017
Laquinimod Safety Profile: Pooled Analyses from the ALLEGRO and BRAVO TrialsPer Soelberg Sørensen, Giancarlo Comi, Timothy L Vollmer, et al.
Epilepsia|April 2, 2021
Time to onset of cannabidiol (CBD) treatment effect in Lennox-Gastaut syndrome: Analysis from two randomized controlled trialsMichael Privitera, Hari Bhathal, Matthew Wong, et al.
JAMA Neurology|March 3, 2020
Dose-Ranging Effect of Adjunctive Oral Cannabidiol vs Placebo on Convulsive Seizure Frequency in Dravet Syndrome: A Randomized Clinical TrialIan Miller, Ingrid E Scheffer, Boudewijn Gunning, et al.
JAMA Neurology|December 21, 2020
Add-on Cannabidiol Treatment for Drug-Resistant Seizures in Tuberous Sclerosis Complex: A Placebo-Controlled Randomized Clinical TrialElizabeth A Thiele, E Martina Bebin, Hari Bhathal, et al.
Acta Neuropathologica|July 5, 2014
CD19 as a molecular target in CNS autoimmunityOlaf Stüve, Clemens Warnke, Krystin Deason, et al.
Pageof 5